Multimodal R&D Management with Incyte's Jim Lee, M.D., Ph.D.
Jan 22, 2024
auto_awesome
In this podcast, Dr. Jim Lee, head of Inflammation and Autoimmunity at Incyte, discusses the company's multimodal approach to R&D. They explore the impact of a multimodal approach in drug development, specifically in dermatology. They also discuss the connection between inflammation, oncology, and dermatology, as well as their advancements in dermatology and future plans. Additionally, they touch on the role of biologics in dermatology and the impact of having a celebrity spokesperson for patient awareness. Dr. Lee concludes by discussing upcoming milestones in R&D.
50:31
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Insight Pharmaceuticals prioritizes patient-centric drug development, utilizing both small molecules and biologics to target various diseases.
Data-driven decision making and a patient-oriented approach are key factors in Insight Pharmaceuticals' successful R&D management.
Deep dives
Insight's Multimodal Approach to Drug Development
Insight Pharmaceuticals takes a multimodal approach to drug development, prioritizing the patient and utilizing the best science. They focus on developing drugs for patients regardless of whether they are small molecules or biologics. By exploring diseases and potential targets, they determine the best approach for drug development. This approach has led to success in oncology, inflammation, blood disorders, GVHD, and their recent endeavor into dermatology. Insight structures its R&D function by clinical development, research, and chemistry, with a matrix team-based approach for project work.
The Importance of Data-Driven Decision Making in R&D
In managing R&D and pipeline progress, Insight Pharmaceuticals emphasizes data-driven decision making. They recognize the complexity of developing drugs for patients and the necessity of prioritization. The organization stays focused on patients and uses data objectively to make informed decisions. While emotional investment in projects can complicate decision making, data remains the fundamental guide in determining the potential impact on patients. The company's collaborative and patient-oriented approach ensures that decisions are made in the best interest of patients.
Insight's Contribution to Dermatology
Insight Pharmaceuticals has made significant progress in the field of dermatology. Their recent commercial win in the dermatology space is fueled by their multimodal approach and the addition of Dr. Jim Lee, who heads the Inflammation and Autoimmunity division. They have developed Ruxolitinib, a topical JAK inhibitor, for the treatment of skin conditions such as eczema and vitiligo. Additionally, they are exploring new indications and age ranges for Ruxolitinib cream, working on an oral JAK inhibitor, and developing an anti-IL-15 receptor beta monoclonal antibody. Insight continues to invest in dermatology and other inflammatory disorders to provide better treatment options for patients.
Maintaining Patient Connection in R&D
While maintaining a patient-centric approach is challenging in the R&D environment, Insight Pharmaceuticals takes steps to keep the patient at the forefront. They remind their employees of the impact their work has on patients and organize interactions with patients to show the direct impact of their research. Attending scientific meetings and conferences also helps maintain the connection to patient needs and challenges. While the connection may not always be direct in the lab, the overarching goal of improving patient outcomes keeps the focus on making a difference in patients' lives.
Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of Biotech, and that’s okay! Sometimes, the smartest approach to creating your own masterpiece is to study the masters On this episode of the podcast, we sit down with Incyte’s Group Vice President and head of its Inflammation and AutoImmunity Group, Jim Lee, M.D., Ph.D. for a dissection of the company’s approach to the comprehensive and efficient R&D that leads to repeated clinical and commercial success.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.